USA, Smithfield, Va. An announcement by Smithfield Foods Inc. detailed a new strategic platform based on using the byproducts of meat processing to develop pharmaceuticals, nutraceuticals and medical device solutions. The company plans to take a leadership position in the development and support of a range of biotechnology solutions in human therapeutics, tissue fabrication and regenerative medicine.
Currently Smithfield sells byproducts to companies that develop drugs used to treat issues ranging from indigestion to hypothyroidism to deep vein thrombosis. Smithfield Bioscience will take these efforts a step further by focusing on processes such as tissue regeneration and the availability of viable, human, transplant organs.
Smithfield Bioscience has joined in participating in the Advanced Regenerative Manufacturing Institute (ARMI) as one of its first projects. The public-private US manufacturing initiative has brought 100 academic, robotic and pharmaceutical organizations together to develop future technologies and manufacturing processes for cell, tissue and organ development.
The US Dept. of Defense has provided funding for the group and it will initially focus on the technology that enables the repair and replacement of tissues of soldiers injured during combat. Smithfield Science will also work on immunology therapy with Harvard Medical School and Columbia Univ.